Karin Berger

About Karin Berger

Karin Berger, With an exceptional h-index of 32 and a recent h-index of 18 (since 2020), a distinguished researcher at Ludwig-Maximilians-Universität München, specializes in the field of Health Care Research, Health Economics, Outcome Research.

His recent articles reflect a diverse array of research interests and contributions to the field:

Supplementary material Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

EPH163 Burden of Diffuse Large B-Cell Lymphoma (DLBCL) in Germany–A Retrospective Statutory Health Insurance Claims Data Analysis

Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Usability of German hospital administrative claims data for healthcare research: General assessment and use case of multiple myeloma in Munich university hospital in 2015–2017

Budget impact analysis of CAR T-cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Germany

Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective

Transparency on Platelet Transfusion in Routine Cancer Care: The Key for Optimal Blood Usage?

Karin Berger Information

University

Position

Senior Scientist University Hospital Munich

Citations(all)

4548

Citations(since 2020)

1189

Cited By

3709

hIndex(all)

32

hIndex(since 2020)

18

i10Index(all)

68

i10Index(since 2020)

33

Email

University Profile Page

Google Scholar

Karin Berger Skills & Research Interests

Health Care Research

Health Economics

Outcome Research

Top articles of Karin Berger

Supplementary material Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

2024/2/1

Julia Mayerle
Julia Mayerle

H-Index: 54

Karin Berger
Karin Berger

H-Index: 19

Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

2023/10

EPH163 Burden of Diffuse Large B-Cell Lymphoma (DLBCL) in Germany–A Retrospective Statutory Health Insurance Claims Data Analysis

Value in Health

2022/12/1

Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Haemophilia: the official journal of the World Federation of Hemophilia

2022/11

Karin Berger
Karin Berger

H-Index: 19

Usability of German hospital administrative claims data for healthcare research: General assessment and use case of multiple myeloma in Munich university hospital in 2015–2017

PloS one

2022/7/28

Budget impact analysis of CAR T-cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Germany

Hemasphere

2022/7/1

Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective

Clinical Lymphoma Myeloma and Leukemia

2022/7/1

Transparency on Platelet Transfusion in Routine Cancer Care: The Key for Optimal Blood Usage?

2022/6/16

Karin Berger
Karin Berger

H-Index: 19

1518P Treating cancer with unknown primary (CUP) in Germany–an economic perspective

Annals of Oncology

2021/9/1

Primary and secondary data analysis on the care situation of patients with venous thrombosis and cancer in Bavaria

Oncology Research and Treatment

2021

Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement …

Haematologica

2020/8

Flora Peyvandi
Flora Peyvandi

H-Index: 49

Karin Berger
Karin Berger

H-Index: 19

Epidemiology, patient adherence, and costs of oral mucositis in routine care in stem cell transplantation

Supportive Care in Cancer

2020/7

Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source

Aging Clinical and Experimental Research

2020/6

Irena Cenzer
Irena Cenzer

H-Index: 25

Karin Berger
Karin Berger

H-Index: 19

Performance of matching methods in studies of rare diseases: a simulation study

Intractable & Rare Diseases Research

2020/5/31

Irena Cenzer
Irena Cenzer

H-Index: 25

Karin Berger
Karin Berger

H-Index: 19

A multiyear cross‐sectional study of US national prescribing patterns of first‐generation sedating antihistamines in older adults with skin disease

British Journal of Dermatology

2020/3/1

See List of Professors in Karin Berger University(Ludwig-Maximilians-Universität München)